![Alexander Sapir](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alexander Sapir
Directeur Général chez
FULCRUM THERAPEUTICS, INC.
Fortune : 735 364 $ au 30/06/2026
Profil
Mr. Alexander C.
Sapir is a President, Chief Executive Officer & Director at Fulcrum Therapeutics, Inc., an Independent Director at PhaseBio Pharmaceuticals, Inc. and a Chief Executive Officer & Director at ReViral Ltd. He is on the Board of Directors at Fulcrum Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and ReViral Ltd. Mr. Sapir was previously employed as a President, Chief Executive Officer & Director by Dova Pharmaceuticals, Inc., an Executive Vice President-Marketing & Sales by United Therapeutics Corp., and a Senior Director-Marketing by Guilford Pharmaceuticals, Inc. He received his undergraduate degree from Franklin & Marshall College and an MBA from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 200 919 ( 0,3 % ) | 735 364 $ | 30/06/2026 |
Postes actifs de Alexander Sapir
| Sociétés | Poste | Début |
|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 12/02/2020 |
| FULCRUM THERAPEUTICS, INC. | Directeur Général | 01/07/2023 |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Directeur Général | 10/06/2019 |
Anciens postes connus de Alexander Sapir
| Sociétés | Poste | Fin |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Directeur Général | 01/12/2018 |
| UNITED THERAPEUTICS CORPORATION | Sales & Marketing | 01/05/2016 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Sales & Marketing | 01/01/2005 |
Formation de Alexander Sapir
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
61
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Health Technology |
United Therapeutics Corp.
 United Therapeutics Corp. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic & life-threatening conditions | Health Technology |
PhaseBio Pharmaceuticals, Inc.
 PhaseBio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapies for cardiovascular diseases | Health Technology |
Franklin & Marshall College
 Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Health Technology |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
